Human tumor antigens recognized by T-cells

T-cells play an important role in in vivo tumor rejection in many animal tumor models and in human melanoma. Many human tumor antigens recognized by autologous T-cells have now been identified. These are found to be nonmutated and mutated peptides derived from various self proteins as well as viral proteins. A variety of mechanisms involved in generating these T-cell epitopes on growing cancers have also been identified. However, the role of these identified antigens remains to be evaluated. Passive or active immunotherapies using these identified tumor antigens are being conducted in many institutions. The results obtained from these clinical trials may give us better insight into the role of T-cell responses to each antigen in tumor rejection as well as the development of new antigen-specific immunotherapies for patients with cancer.

[1]  C. Figdor,et al.  Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. , 1993, The American journal of pathology.

[2]  C. Figdor,et al.  Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line , 1995, International journal of cancer.

[3]  B. Moss,et al.  IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. , 1996, Journal of immunology.

[4]  M. Gonda,et al.  Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. , 1997, Journal of immunological methods.

[5]  S. Rosenberg,et al.  Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.

[6]  S. Rosenberg,et al.  Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. , 1996, Cancer research.

[7]  P. Coulie,et al.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[8]  A. Houghton,et al.  Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. , 1995, Journal of immunology.

[9]  M. Lotze,et al.  Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes , 1995, The Journal of experimental medicine.

[10]  S. Rosenberg,et al.  Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Srivastava,et al.  Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. , 1994, Journal of immunology.

[12]  D. Hunt,et al.  Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. , 1996, Journal of immunology.

[13]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[14]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[15]  S. Rosenberg,et al.  Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Old,et al.  A pigmentation‐associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum , 1983, International journal of cancer.

[17]  A Sette,et al.  Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. , 1995, Journal of immunology.

[18]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[19]  A. Agulnik,et al.  The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. , 1997, Immunity.

[20]  J. Schiller,et al.  Human papillomavirus immunology and vaccine prospects. , 1996, Journal of the National Cancer Institute. Monographs.

[21]  S. Rosenberg,et al.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.

[22]  S. Rosenberg,et al.  Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.

[23]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[24]  S. Rosenberg,et al.  Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. , 1996, Journal of immunology.

[25]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[26]  S. Rosenberg,et al.  Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. , 1992, Journal of immunology.

[27]  F. Brasseur,et al.  A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma , 1996, The Journal of experimental medicine.

[28]  A. Sette,et al.  Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. , 1996, Cancer research.

[29]  S. Rosenberg,et al.  Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. , 1990, Journal of immunology.

[30]  E. Gilboa,et al.  Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts , 1997, International journal of cancer.

[31]  R. Henderson,et al.  MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines , 1995, Immunological reviews.

[32]  S. Rosenberg,et al.  Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. , 1997, Cancer research.

[33]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[34]  P. Bruggen,et al.  Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601 , 1994, European journal of immunology.

[35]  E. Kieff,et al.  Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  E. Gilboa,et al.  Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo , 1996, The Journal of experimental medicine.

[37]  K. Sakaguchi,et al.  Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. , 1995, Journal of immunology.

[38]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[39]  S. Rosenberg,et al.  Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261] , 1995, The Journal of experimental medicine.

[40]  H. Grey,et al.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. , 1995, Journal of immunology.

[41]  S. Rosenberg,et al.  Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.

[42]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[43]  K. Sakaguchi,et al.  Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. , 1995, Journal of immunology.

[44]  T. Eberlein,et al.  Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[45]  F. Marincola,et al.  Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.

[46]  J. Cormier,et al.  Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.

[47]  O. D'cruz,et al.  Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. , 1988, American journal of reproductive immunology and microbiology : AJRIM.

[48]  F. Marincola,et al.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. , 1996, Journal of the National Cancer Institute.

[49]  J. Bryant,et al.  Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. , 1996, The Journal of clinical investigation.

[50]  T. Eberlein,et al.  Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. , 1994, Journal of immunology.

[51]  P. Coulie,et al.  A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.

[52]  Paul Polakis,et al.  Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines , 1997, Science.

[53]  R. Metzgar,et al.  Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.

[54]  S. Riddell,et al.  Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. , 1995, The New England journal of medicine.

[55]  B. Moss,et al.  Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. , 1996, Cancer research.

[56]  E. Thorsby,et al.  T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA , 1994, European journal of immunology.

[57]  J. Tschopp,et al.  Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape , 1996, Science.

[58]  A. Gazdar,et al.  HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. , 1994, Cancer research.

[59]  J. Schlom,et al.  Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.

[60]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[61]  L. Fugger,et al.  Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Drijfhout,et al.  Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[63]  A. Anichini,et al.  Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. , 1996, Journal of immunology.

[64]  R. Henderson,et al.  Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. , 1995, Journal of immunology.

[65]  O. de Backer,et al.  A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma , 1995, The Journal of experimental medicine.

[66]  H. Sakamoto,et al.  Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines , 1996, The Journal of experimental medicine.

[67]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[68]  A Sette,et al.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes , 1996, The Journal of experimental medicine.

[69]  E. Thorsby,et al.  p21‐ras‐peptide‐specific T‐cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly → Asp) , 2007, International journal of cancer.

[70]  M. Lotze,et al.  A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. , 1996, The Journal of surgical research.

[71]  F. Brasseur,et al.  A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene , 1996, The Journal of experimental medicine.

[72]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[73]  A. Kirk,et al.  A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis , 1997, Cancer Immunology, Immunotherapy.

[74]  K. Irvine,et al.  The next wave of recombinant and synthetic anticancer vaccines. , 1995, Seminars in cancer biology.

[75]  C. Slingluff,et al.  The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. , 1989, Journal of immunology.

[76]  A. Sette,et al.  Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. , 1996, American journal of obstetrics and gynecology.

[77]  T. Eberlein,et al.  Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. , 1995, Journal of immunology.

[78]  F. Marincola,et al.  Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35) , 1996, The Journal of experimental medicine.

[79]  P. Coulie,et al.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.

[80]  E. Thorsby,et al.  A K‐ras 13GLY → ASP mutation is recognized by HLA‐DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation? , 1994, International journal of cancer.

[81]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[82]  S. Rosenberg,et al.  Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.

[83]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[84]  L. Zitvogel,et al.  Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity , 1995, Nature Medicine.

[85]  E. Thorsby,et al.  Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61). , 1992, International immunology.

[86]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[87]  S. Rosenberg Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. , 1996, Journal of the National Cancer Institute.

[88]  T. Boon,et al.  A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes , 1996, European journal of immunology.

[89]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[90]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[91]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[92]  A Sette,et al.  Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.

[93]  P. Matzinger Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[94]  J. Renauld,et al.  A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.

[95]  S. Rosenberg,et al.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[96]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[97]  S. Rosenberg,et al.  Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen , 1996, The Journal of experimental medicine.

[98]  S. Rosenberg,et al.  Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells , 1994, International journal of cancer.

[99]  N. Cascinelli,et al.  Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3 , 1995, International journal of cancer.

[100]  E. Gilboa,et al.  Antigen‐presenting cells pulsed with unfractionated tumor‐derived peptides are potent tumor vaccines , 1997, European journal of immunology.

[101]  R. Brasseur,et al.  BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. , 1995, Immunity.

[102]  R. Offringa,et al.  Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[103]  A. Houghton,et al.  Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein , 1995, The Journal of experimental medicine.

[104]  B. Seliger,et al.  Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.

[105]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[106]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[107]  W. Kast,et al.  Induction and characterization of cytotoxic T‐lymphocytes recognizing a mutated p21ras peptide presented by HLA‐A*0201 , 1995, International journal of cancer.

[108]  E. Appella,et al.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes , 1996, The Journal of experimental medicine.

[109]  E. Kieff,et al.  Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies , 1992, The Journal of experimental medicine.

[110]  J. Sidney,et al.  Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. , 1997, Journal of immunology.

[111]  S. Rosenberg,et al.  T-cell recognition of human melanoma antigens. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[112]  W. Storkus,et al.  B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .

[113]  J. Renauld,et al.  Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes , 1995, Immunological reviews.

[114]  M. Herlyn,et al.  Melanoma cells and normal melanocytes share antigens recognized by HLA- A2-restricted cytotoxic T cell clones from melanoma patients , 1993, The Journal of experimental medicine.

[115]  S. Rosenberg,et al.  The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. , 1997, Journal of immunology.

[116]  S. Rosenberg,et al.  Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[117]  P. Sismondi,et al.  Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.

[118]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[119]  J. Schlom,et al.  In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. , 1997, Journal of the National Cancer Institute.

[120]  S. Rosenberg,et al.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.

[121]  S. Rosenberg,et al.  T-cell recognition of self peptides as tumor rejection antigens , 1996, Immunologic research.

[122]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[123]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[124]  O. de Backer,et al.  The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[125]  Edgar G. Engleman,et al.  Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.

[126]  M. Perricaudet,et al.  Induction of a cytolytic T‐cell response in mice with a recombinant adenovirus coding for tumor antigen P815A , 1996, International journal of cancer.

[127]  S. H. van der Burg,et al.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.

[128]  P. Duray,et al.  Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[129]  J. Berzofsky,et al.  Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif. , 1994, Cancer research.

[130]  Y. Hinoda,et al.  Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. , 1994, Journal of immunology.